首页 | 本学科首页   官方微博 | 高级检索  
检索        


A phase II study of gemcitabine,carboplatin and bevacizumab for the treatment of platinum-sensitive recurrent ovarian cancer
Authors:Eric L Eisenhauer  Vanna Zanagnolo  David E Cohn  Ritu Salani  David M O'Malley  Gregory Sutton  Michael J Callahan  Bobbi Cobb  Jeffrey M Fowler  Larry J Copeland
Institution:1. Division of Gynecologic Oncology, The Ohio State University College of Medicine, Columbus, OH, USA;2. Division of Gynaecology, European Institute of Oncology, Milano, Italy;3. Division of Gynecologic Oncology, St. Vincent Indianapolis Hospital, Indianapolis, IN, USA
Abstract:

Purpose

The doublet gemcitabine and carboplatin is effective for the treatment of recurrent ovarian cancer, while multi-agent chemotherapy with bevacizumab may add additional benefit. This phase II study tested the efficacy and safety of a biweekly gemcitabine, carboplatin, and bevacizumab combination in patients with platinum-sensitive recurrent ovarian, peritoneal, or tubal cancer (ROC).

Patients and methods

Eligible patients received concurrent gemcitabine 1000 mg/m2, carboplatin area under the curve 3, and bevacizumab 10 mg/kg administered intravenously on days 1 and 15 every 28 days for six cycles or up to 24 cycles if clinical benefit occurred. The primary end points were progression-free survival (PFS) by RECIST, and safety; the secondary end points were objective response rates and overall survival.

Results

Overall, 45 patients were enrolled. The median PFS was 13.3 months (95% CI, 11.3 to 15.3). The objective response rate was 69%. Grade 4 hematologic toxicities included neutropenia (27%) and thrombocytopenia (2%). Grades 3 and 4 non-hematologic toxicities included fatigue (18%), pain (9%), and nausea/vomiting (4%). There were 2 episodes of cerebrovascular accidents, 2 noted DVTs, and no episodes of bowel perforation. Median OS was 36.1 months (95% CI, 26.7 to 45.5).

Conclusion

Biweekly gemcitabine, carboplatin, and bevacizumab were an effective regimen in recurrent ovarian cancer, with comparable toxicity to recently reported day 1 gemcitabine, carboplatin, bevacizumab, and day 8 gemcitabine. Response rate and PFS are improved from reported outcomes of the gemcitabine carboplatin doublet. The degree to which biweekly dosing may present a more rationale schedule for this triplet should be evaluated further.
Keywords:Ovarian cancer  Chemotherapy  Platinum-sensitive  Recurrent  Gemcitabine  Bevacizumab
本文献已被 ScienceDirect 等数据库收录!
设为首页 | 免责声明 | 关于勤云 | 加入收藏

Copyright©北京勤云科技发展有限公司  京ICP备09084417号